FES scan to guide tamoxifen for metastatic breast cancer
Treatments studied
Part of Cancer clinical trials.
This early-phase study uses a special PET scan (FES PET/CT) to better match tamoxifen treatment to people with estrogen-receptor–positive breast cancer that has spread. It aims to see whether the scan results can help optimize tamoxifen use and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that is metastatic (spread) or cannot be removed by surgery
- Your tumor tests show estrogen receptors are at least 10%, and you have a specific ESR1 mutation (from biopsy tissue or blood)
- Your cancer must be HER2 negative, based on lab testing
- You must have measurable disease, or evaluable bone-only disease that includes at least one bone area 10 mm or larger (no liver-only disease)
- You must have had at least 1 prior hormone (endocrine) treatment for metastatic cancer or the cancer must have progressed within 12 months of hormone treatment given after diagnosis surgery
- Your health checks must be adequate (blood counts and organ/liver/kidney function), and your energy level must be ECOG 0–1
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan called 4FMFES-PET to take detailed pictures of ER-positive breast cancer that has spread. It helps doctors see where the cancer is and how active it is, which may guide treatment decisions.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
This trial is testing a special PET scan (18F-FES PET/CT) to see if it can find distant cancer spread in women with a slow-growing, estrogen receptor-positive, stage III breast cancer. The goal is to find out whether this imaging test can detect hidden metastases better than standard scans.
This Phase 2 study tests how well a special PET/CT scan (called FES PET/CT) can find uterine cancer and its spread. It may help doctors see where cancer is active, which can guide future treatment decisions.
This trial tests a special PET scan called FES to see if it can detect estrogen receptors in brain metastases. It may help doctors better target treatment for people with ER+ breast cancer that has spread to the brain.
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.